AbbVie Corporation v. Canada (Health), 2022 FC 1538 (Adalimumab*)
Justice Fothergill - 2022-11-10
Read full decision. Automatically generated summary:
JAMP has brought a motion in writing pursuant to Rule 369 of the Rules, for an award of costs or, alternatively, an Order pursuant to Rules 400 and 403 providing directions to the assessment officer respecting the amount and allocation of costs. In 2022 FC 1209, this Court dismissed two applications for judicial review brought on behalf of AbbVie, with costs payable to both the Minister and JAMP. AbbVie challenged two decisions of the Minister made pursuant to the PM(NOC) Regulations. The Court held that the Minister reasonably found JAMP not to be a “second person” under s 5(1) of the PM(NOC) Regulations in respect of its new drug submission for SIMLANDI, a biosimilar of Abbvie’s HUMIRA. ... For the reasons that follow, the assessment officer is directed to award JAMP costs, including reasonable disbursements, in accordance with the high end of Column IV of Tariff B of the Rules.
Decision relates to:
- T-10-22 - AbbVie Corporation et Al. v. Minister of Health et Al.
- T-130-22 - ABBVIE CORPORATION et Al. v. THE MINISTER OF HEALTH et Al.